Literature DB >> 22251423

NAMPT (visfatin) and AKT1 genetic variants associate with myocardial infarction.

Karin Leander1, Bruna Gigante, Angela Silveira, Max Vikström, Anders Hamsten, Johan Högberg.   

Abstract

BACKGROUND: High plasma levels of the adipokine NAMPT (or visfatin) have been associated with cardiovascular disease. However experimental data suggest that NAMPT, via Akt signaling, protects the myocardium against hypoxic insults. We studied whether the NAMPT rs1319501, AKT1 rs3730358, p53 rs1042522, Mdm2 rs2279744 or eNOS rs1799983 SNP:s linked to NAMPT and Akt signaling associate with risk of myocardial infarction (MI).
METHODS: Cases were 828 men and 346 women aged 45-70 who had suffered a first MI. Control individuals, 1062 men and 513 women, were randomly chosen from the study base. We employed unconditional logistic regression analysis.
RESULTS: The rs1319501 minor allele associated with MI among women aged 45-60; odds ratio (OR) under a recessive model of inheritance: 2.96 (95% confidence interval [CI] 1.06-8.29). Replication analysis in an independent material yielded OR point estimates in the same direction. The rs3730358 minor allele associated with low MI risk in men aged 45-60 (OR dominant model: 0.72, 95% CI 0.53-0.97), an association completely attenuated by adjusting for inflammatory markers.
CONCLUSIONS: The NAMPT rs1319501 minor allele associates with increased MI risk in young women. In young men a protective effect of the AKT1 rs3730358 minor allele was suggested, possibly related to an attenuated inflammation. Copyright Â
© 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22251423     DOI: 10.1016/j.cca.2012.01.002

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

1.  Gene-gene interactions in the NAMPT pathway, plasma visfatin/NAMPT levels, and antihypertensive therapy responsiveness in hypertensive disorders of pregnancy.

Authors:  M R Luizon; A C T Palei; V A Belo; L M Amaral; R Lacchini; G Duarte; R C Cavalli; V C Sandrim; J E Tanus-Santos
Journal:  Pharmacogenomics J       Date:  2016-05-10       Impact factor: 3.550

2.  Effects of NAMPT polymorphisms and haplotypes on circulating visfatin/NAMPT levels in hypertensive disorders of pregnancy.

Authors:  Marcelo R Luizon; Vanessa A Belo; Ana Ct Palei; Lorena M Amaral; Riccardo Lacchini; Valeria C Sandrim; Geraldo Duarte; Ricardo C Cavalli; Jose E Tanus-Santos
Journal:  Hypertens Res       Date:  2015-02-26       Impact factor: 3.872

3.  Genetic variants in NAMPT predict bladder cancer risk and prognosis in individuals from southwest Chinese Han group.

Authors:  Kui Zhang; Bin Zhou; Peng Zhang; Zhu Zhang; Peng Chen; Yan Pu; Yaping Song; Lin Zhang
Journal:  Tumour Biol       Date:  2013-12-22

4.  The effects of NAMPT haplotypes and metabolic risk factors on circulating visfatin/NAMPT levels in childhood obesity.

Authors:  V A Belo; M R Luizon; R Lacchini; J A Miranda; C M M Lanna; D C Souza-Costa; J E Tanus-Santos
Journal:  Int J Obes (Lond)       Date:  2013-09-12       Impact factor: 5.095

5.  The NAMPT promoter is regulated by mechanical stress, signal transducer and activator of transcription 5, and acute respiratory distress syndrome-associated genetic variants.

Authors:  Xiaoguang Sun; Venkateswaran Ramamoorthi Elangovan; Brandon Mapes; Sara M Camp; Saad Sammani; Laleh Saadat; Ermelinda Ceco; Shwu-Fan Ma; Carlos Flores; Matthew S MacDougall; Hector Quijada; Bin Liu; Carrie L Kempf; Ting Wang; Eddie T Chiang; Joe G N Garcia
Journal:  Am J Respir Cell Mol Biol       Date:  2014-11       Impact factor: 6.914

6.  Analysis of the role of interleukin 6 receptor haplotypes in the regulation of circulating levels of inflammatory biomarkers and risk of coronary heart disease.

Authors:  Bruna Gigante; Rona J Strawbridge; Ilais Moreno Velasquez; Zahra Golabkesh; Angela Silveira; Anuj Goel; Damiano Baldassarre; Fabrizio Veglia; Elena Tremoli; Robert Clarke; Hugh Watkins; Anders Hamsten; Steve E Humphries; Ulf de Faire
Journal:  PLoS One       Date:  2015-03-17       Impact factor: 3.240

7.  Association of circulating levels of nicotinamide phosphoribosyltransferase (NAMPT/Visfatin) and of a frequent polymorphism in the promoter of the NAMPT gene with coronary artery disease in diabetic and non-diabetic subjects.

Authors:  Pedro Saddi-Rosa; Carolina Oliveira; Felipe Crispim; Fernando M A Giuffrida; Valter de Lima; José Vieira; Alessandro Doria; Gilberto Velho; André Reis
Journal:  Cardiovasc Diabetol       Date:  2013-08-22       Impact factor: 9.951

8.  Association of Nicotinamide Phosphoribosyltransferase (NAMPT) Gene Polymorphisms and of Serum NAMPT Levels with Dilated Cardiomyopathy in a Chinese Population.

Authors:  Qingyu Dou; Ying Peng; Bin Zhou; Kui Zhang; Jing Lin; Xiaohui Dai; Lin Zhang; Li Rao
Journal:  Int J Mol Sci       Date:  2015-09-15       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.